Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Crinetics Pharmaceuticals, Inc. by Quarter
Crinetics Pharmaceuticals, Inc. (CIK 0001699813, July 2026 acquisition agreement for PALSONIFY, ~$8.8B) — R&D expense ($M) ($M)
Vertex Pharmaceuticals Crinetics Pharmaceuticals, Inc.: $99.9M in Q2 2026, up 24.3% from a year earlier.
Where the Q2 2026 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001699813 Crinetics Pharmaceuticals, Inc., FY2018–FY2026Q2).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Crinetics Pharmaceuticals, Inc. (CIK 0001699813, July 2026 acquisition agreement for PALSONIFY, ~$8.8B) — R&D expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 99.9 | +24.3% | SEC Filing ↗ |
| Q1 2026 | Mar 31, 2026 | 100 | +31.3% | SEC Filing ↗ |
| Q4 2025 | Dec 31, 2025 | 85.1 | +27.8% | SEC Filing ↗ |
| Q3 2025 | Sep 30, 2025 | 90.5 | +46.1% | SEC Filing ↗ |
| Q2 2025 | Jun 30, 2025 | 80.3 | +37.6% | SEC Filing ↗ |
| Q1 2025 | Mar 31, 2025 | 76.2 | +42.9% | SEC Filing ↗ |
| Q4 2024 | Dec 31, 2024 | 66.6 | +46.1% | SEC Filing ↗ |
| Q3 2024 | Sep 30, 2024 | 61.9 | +41.2% | SEC Filing ↗ |
| Q2 2024 | Jun 30, 2024 | 58.3 | +43.6% | SEC Filing ↗ |
| Q1 2024 | Mar 31, 2024 | 53.3 | +38.7% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | 45.6 | +23.2% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | 43.8 | +37.0% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 40.6 | +23.2% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 38.5 | +36.2% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 37.0 | +50.4% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | 32.0 | +48.2% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 33.0 | +61.0% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 28.3 | +60.7% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 24.6 | +46.2% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 21.6 | +57.5% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 20.5 | +62.5% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 17.6 | +26.8% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 16.8 | +38.6% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 13.7 | +15.9% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 12.6 | +22.5% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 13.9 | +91.2% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 12.1 | +58.7% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 11.8 | +71.6% | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | 10.3 | +97.1% | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | 7.25 | +53.6% | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | 7.65 | – | SEC Filing ↗ |
| Q3 2018 | Sep 30, 2018 | 6.89 | – | SEC Filing ↗ |
| Q2 2018 | Jun 30, 2018 | 5.22 | – | SEC Filing ↗ |
| Q1 2018 | Mar 31, 2018 | 4.72 | – | SEC Filing ↗ |
Breakdown
What makes up crinetics Pharmaceuticals, Inc.
- Crinetics Pharmaceuticals — Total revenues ($M)25.1 · Q2 2026
- Crinetics Pharmaceuticals — Operating loss ($M)-132 · Q2 2026
- Crinetics Pharmaceuticals — Net loss ($M)-121 · Q2 2026
- Crinetics Pharmaceuticals — Stock-based compensation expense ($M)24.9 · Q2 2026
- Crinetics Pharmaceuticals — Cash and cash equivalents ($M)55.5 · Q2 2026
- Crinetics Pharmaceuticals — Investment securities ($M)1,150 · Q2 2026
- Crinetics Pharmaceuticals — Total assets ($M)1,322 · Q2 2026
- Crinetics Pharmaceuticals — Total liabilities ($M)130 · Q2 2026
- Crinetics Pharmaceuticals — Stockholders' equity ($M)1,192 · Q2 2026
Cite this data
StockData. (2026). Vertex Pharmaceuticals Crinetics Pharmaceuticals, Inc. ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crinetics-rd-exp
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.